RNA interference targeting the M2 subunit of ribonucleotide reductase enhances pancreatic adenocarcinoma chemosensitivity to gemcitabine (Q40609648)

https://doi.org/10.1038/s41388-023-02627-4

22 September 2017

1 reference

29 December 2023

https://retractionwatch.com/2023/02/14/harvard-surgeon-has-five-papers-pulled-following-internal-investigation/

title

RNA interference targeting the M2 subunit of ribonucleotide reductase enhances pancreatic adenocarcinoma chemosensitivity to gemcitabine (English)

1 reference

pancreatic adenocarcinoma

22 September 2017

1 reference

1 reference

1 reference

Mark S Duxbury

1

1 reference

22 September 2017

Hiromichi Ito

2

1 reference

22 September 2017

Michael J Zinner

3

1 reference

22 September 2017

Stanley W Ashley

4

1 reference

22 September 2017

Edward E Whang

5

1 reference

22 September 2017

language of work or name

English

0 references

publication date

1 February 2004

1 reference

22 September 2017

1 reference

22 September 2017

23

1 reference

22 September 2017

8

1 reference

22 September 2017

1539-1548

1 reference

https://scigraph.springernature.com/pub.10.1038/sj.onc.1207272

22 September 2017

0 references

cites work

RNA interference may be more potent than antisense RNA in human cancer cell lines

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1207272

Comparison of antisense oligonucleotides and siRNAs in cell culture and in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1207272

Hydroxyurea inhibits the transactivation of the HIV-long-terminal repeat (LTR) promoter

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1207272

The biochemistry of P-glycoprotein-mediated multidrug resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1207272

Ribonucleotide reductase R2 component is a novel malignancy determinant that cooperates with activated oncogenes to determine transformation and malignant potential

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1207272

Control of metastatic properties of BL6 melanoma cells by H-2Kb gene: immunological and nonimmunological mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1207272

Mammalian p53R2 protein forms an active ribonucleotide reductase in vitro with the R1 protein, which is expressed both in resting cells in response to DNA damage and in proliferating cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1207272

NF-kappaB in pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1207272

Altered expression of ribonucleotide reductase and role of M2 gene amplification in hydroxyurea-resistant hamster, mouse, rat, and human cell lines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1207272

Human ribonucleotide reductase M2 subunit gene amplification and transcriptional regulation in a homogeneous staining chromosome region responsible for the mechanism of drug resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1207272

Overexpression of transfected human ribonucleotide reductase M2 subunit in human cancer cells enhances their invasive potential

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1207272

Role of NF-kappaB and Akt/PI3K in the resistance of pancreatic carcinoma cell lines against gemcitabine-induced cell death

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1207272

7 January 2021

Determinants of resistance to 2',2'-difluorodeoxycytidine (gemcitabine).

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1207272

7 January 2021

A system for stable expression of short interfering RNAs in mammalian cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1207272

7 January 2021

Stable suppression of tumorigenicity by virus-mediated RNA interference

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1207272

7 January 2021

Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1207272

7 January 2021

Didox (a novel ribonucleotide reductase inhibitor) overcomes Bcl-2 mediated radiation resistance in prostate cancer cell line PC-3.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1207272

7 January 2021

Cancer statistics, 2003.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1207272

7 January 2021

CaSm/gemcitabine chemo-gene therapy leads to prolonged survival in a murine model of pancreatic cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1207272

7 January 2021

Selection of optimal kappa B/Rel DNA-binding motifs: interaction of both subunits of NF-kappa B with DNA is required for transcriptional activation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1207272

7 January 2021

Elevated expression of M1 and M2 components and drug-induced posttranscriptional modulation of ribonucleotide reductase in a hydroxyurea-resistant mouse cell line.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1207272

7 January 2021

Usage of the NF-kappaB inhibitor sulfasalazine as sensitizing agent in combined chemotherapy of pancreatic cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1207272

7 January 2021

Modulation of the classical multidrug resistance (MDR) phenotype by RNA interference (RNAi).

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1207272

7 January 2021

Sequence analysis of the large and small subunits of human ribonucleotide reductase

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1207272

7 January 2021

Tumor necrosis factor alpha regulates expression of the major histocompatibility complex class II-associated invariant chain by binding of an NF-kappa B-like factor to a promoter element

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1207272

7 January 2021

Binding and biological effects of tumor necrosis factor and gamma interferon in human pancreatic carcinoma cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1207272

7 January 2021

Multiple transcription factor profiling by enzyme-linked immunoassay

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1207272

7 January 2021

A ribonucleotide reductase gene involved in a p53-dependent cell-cycle checkpoint for DNA damage

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1207272

7 January 2021

Isolation and characterization of expressible cDNA clones encoding the M1 and M2 subunits of mouse ribonucleotide reductase

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1207272

7 January 2021

Ribonucleotide reductase and deoxyribonucleotide pools.

1 reference

COCI

https://opencitations.net/index/api/v1/references/10.1038/SJ.ONC.1207272

30 December 2023

1 reference

https://opencitations.net/index/api/v1/references/10.1038/SJ.ONC.1207272

30 December 2023

Identifiers

DOI

10.1038/SJ.ONC.1207272

1 reference

Dimensions Publication ID

22 September 2017

0 references

1 reference